OCUP News and Press, Ocuphire Pharma Inc Com From 03/15/21

Intec Pharma Ltd (NTEC) +142% on announcing merger agreement with Decoy Biosystems.Check-Cap Ltd. (CHEK) +113% after receiving FDA IDE approval for pivotal study of C-Scan®.Acer Therapeutics (ACER) +67%.Shaw Communications (SJR) +55% as Rogers to acquire the company in C$2...

Ocuphire Pharma (OCUP) jumps 37% premarket after announcing positive top line results in the MIRA-2 Phase 3 registration trial investigating Nyxol for reversal of pharmacologically induced mydriasis (dilation of pupil for eye exams).MIRA-2 trial met its primary endpoint with 49% of ...

Ocuphire Pharma (OCUP): FY GAAP EPS of -$5.28.Cash and cash equivalents of $16.4M.Press Release For further details see: Ocuphire Pharma reports FY results

FARMINGTON HILLS, Mich., March 10, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced financial results for the f...

Efficacy Across Mydriatic Agents in Reversing Pharmacologically Induced Mydriasis Informed Phase 3 Registration MIRA-2 Study Design Topline Results for Phase 3 MIRA-2 Trial Expected in March 2021 FARMINGTON HILLS, Mich., March 05, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, In...

HC Wainwright Life Sciences Conference beginning at 7:00 am ET on March 9th Oppenheimer Healthcare Conference at 9:20 am ET on March 18th FARMINGTON HILLS, Mich., March 04, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceut...

Nyxol and Low-Dose (0.4%) Pilocarpine Combination to Target Improvement in Near Vision in a Presbyopic Population Top Line Data from VEGA-1 Expected End of 2Q21 FARMINGTON HILLS, Mich., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ...

FARMINGTON HILLS, Mich., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that Mina Sooch, Chief Execu...

Ocuphire Pharma (OCUP) announced that results from its ORION-1 (NCT03960866) Phase 2 clinical trial evaluating the safety and efficacy of Nyxol® in glaucoma and presbyopia have been published in the peer-reviewed, open access journal, Clinical Ophthalmology.Key findin...

Durability of Nyxol’s Pupil Constricting Effects Using an Evening Dosing Regimen Informs Dosing Strategy for Phase 2 Trial in Presbyopia and Phase 3 Trial in NVD Ocuphire Invited to Present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase on Jan...